{"id":"https://genegraph.clinicalgenome.org/r/b41906d0-3ed2-4353-ae38-62bad80e8142v2.1","type":"EvidenceStrengthAssertion","dc:description":"*KCNJ11* was first reported in relation to autosomal dominant monogenic diabetes in 2004 (Gloyn et al., PMID: 15115830). Dozens of unique missense variants have been reported in humans in association with diabetes in published cases, with nearly 100 classified as pathogenic or likely pathogenic for diabetes in a recent review article (PMID:  32027066). Evidence supporting this gene-disease relationship includes case-level data and experimental data. Summary of case-level and experimental data: 17 points. Variants in this gene have been reported in at least 26 probands in 9 publications (PMIDs: 15784703, 28938416, 26958039, 27681997, 16670688, 24150202, 16205880, 22701567, 27420379). More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The usual mechanism for disease is heterozygous gain of function (mutated channels remain open due to reduced ATP sensitivity and/or disruption of channel gating and prevent insulin secretion despite hyperglycemia; PMID: 32376986). A single exception to the autosomal dominant inheritance was reported in 2016 in which an infant homozygous for the G324R variant had neonatal diabetes but his heterozygous parents did not have diabetes.  The variant was found to have modestly decreased ATP sensitivity (PMID: 27118464). This gene-disease association is supported by animal models and expression studies. In summary, *KCNJ11* is definitively associated with autosomal dominant monogenic diabetes. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. \n\nPer criteria outline by the ClinGen Lumping and Splitting Working Group, we found differences in molecular mechanisms, inheritance pattern, and phenotypic variability underlying the three disease entities associated with *KCNJ11*. Therefore, we have split curations for these disease entities. The present curation includes (1) autosomal dominant monogenic diabetes, which presents as three phenotypic disease sub-entities: (1A) Permanent neonatal diabetes mellitus, (MIM:606176), (1B) Transient neonatal diabetes, 3 (MIM:125853), and less commonly, (1C) Maturity-onset diabetes of the young, type 13 (MODY13) (MIM:616329). Another entity requiring separate curation is (2) hyperinsulinemic hypoglycemia, familial, 2 (MIM:601820). The role of *KCNJ11* variation in (3) risk for type 2 diabetes (polygenic; MIM:125853) will not be curated at this time since the contribution of *KCNJ11* is in the form of common variants with a small effect.\n\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/b41906d0-3ed2-4353-ae38-62bad80e8142","GCISnapshot":"https://genegraph.clinicalgenome.org/r/9353379e-564a-43bc-a859-7d27ab640e9e","calculatedEvidenceStrength":"Definitive","changes":{"id":"cg:classificationChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/9353379e-564a-43bc-a859-7d27ab640e9e_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10016","date":"2023-01-05T19:51:06.384Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/9353379e-564a-43bc-a859-7d27ab640e9e_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10016","date":"2023-01-05T17:00:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9353379e-564a-43bc-a859-7d27ab640e9e_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4255d59a-18b2-4a28-833d-550a49ebc33e","type":"EvidenceLine","dc:description":"Variant absent from gnomAD, score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4255d59a-18b2-4a28-833d-550a49ebc33e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16670688","allele":{"id":"https://genegraph.clinicalgenome.org/r/e622fbf5-b2e9-420b-88b9-0ae55d504534","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000525.3(KCNJ11):c.602G>A (p.Arg201His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119821"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/8bc0b8e9-c299-444e-9d21-5a3b86ef18e0","type":"EvidenceLine","dc:description":"gnomAD max allele frequency in South Asian population = 0.00003266, score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8bc0b8e9-c299-444e-9d21-5a3b86ef18e0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22701567","allele":{"id":"https://genegraph.clinicalgenome.org/r/d995d52b-8077-42b8-84e5-f7c82aff297c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000525.3(KCNJ11):c.679G>A (p.Glu227Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA172340"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/d7ca6e74-c774-43d9-8388-7c409f46d3ce","type":"EvidenceLine","dc:description":"gnomAD max allele frequency in Ashkenazi Jewish population = 0.00009927, score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7ca6e74-c774-43d9-8388-7c409f46d3ce_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28938416","allele":{"id":"https://genegraph.clinicalgenome.org/r/1f25ca67-00ac-4885-bd06-4d8ae9a94395","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000525.3(KCNJ11):c.868G>A (p.Val290Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5902229"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/da1485a3-1038-488c-bdda-18eff3a33f83","type":"EvidenceLine","dc:description":"Variant reported as NM_000525.3:c.878C>A (p.Thr293Asn) in paper and Allele Registry, variant absent from gnomAD, score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/da1485a3-1038-488c-bdda-18eff3a33f83_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27681997","allele":{"id":"https://genegraph.clinicalgenome.org/r/2a1b6d11-05ac-4bd7-b54c-052df61fef2b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XM_017017680.1(KCNJ11):c.617C>A (p.Thr206Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA379770149"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/381c002b-6177-49e4-b211-8b70c8dd5344","type":"EvidenceLine","dc:description":"gnomAD: max allele frequency in South Asian population = 0.00003266; score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/381c002b-6177-49e4-b211-8b70c8dd5344_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27681997","allele":{"id":"https://genegraph.clinicalgenome.org/r/d995d52b-8077-42b8-84e5-f7c82aff297c"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/4f289737-5dd5-4b0f-9426-fdd384042092","type":"EvidenceLine","dc:description":"Variant reported at NM_000525.3:c.509A>C (p.Lys170Thr) in paper and Allele Registry, variant absent from gnomAD, score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4f289737-5dd5-4b0f-9426-fdd384042092_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27681997","allele":{"id":"https://genegraph.clinicalgenome.org/r/56dc5715-b319-482a-a548-7a242fb0f4bf","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XM_017017680.1(KCNJ11):c.248A>C (p.Lys83Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA379773156"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/2a932feb-b951-4a5f-a070-1445d5da22db","type":"EvidenceLine","dc:description":"Variant reported as NM_000525.3:c.491T>C (p.Leu164Pro) in paper and Allele Registry, variant absent from gnomAD, score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2a932feb-b951-4a5f-a070-1445d5da22db_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27681997","allele":{"id":"https://genegraph.clinicalgenome.org/r/b2c93e6c-4031-4c90-8666-9840f75267ed","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XM_017017680.1(KCNJ11):c.230T>C (p.Leu77Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA379773258"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/516b4131-1ee9-4743-be72-6e322148c95e","type":"EvidenceLine","dc:description":"Variant absent from gnomAD, score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/516b4131-1ee9-4743-be72-6e322148c95e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27681997","allele":{"id":"https://genegraph.clinicalgenome.org/r/b8e6d042-5c70-4859-8eea-2037faf43110","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000525.3(KCNJ11):c.175G>A (p.Val59Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119823"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/8f0cdac0-d4bf-4fe0-8c8c-ec3516aebb97","type":"EvidenceLine","dc:description":"variant absent from gnomAD, score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8f0cdac0-d4bf-4fe0-8c8c-ec3516aebb97_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27681997","allele":{"id":"https://genegraph.clinicalgenome.org/r/e622fbf5-b2e9-420b-88b9-0ae55d504534"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/1c196b1e-0d63-46c4-acfa-f6117b3fbaf2","type":"EvidenceLine","dc:description":"variant absent from gnomAD, score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1c196b1e-0d63-46c4-acfa-f6117b3fbaf2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27681997","allele":{"id":"https://genegraph.clinicalgenome.org/r/802bc63e-2b4e-4e06-aa96-a1c3065b62bc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000525.3(KCNJ11):c.149G>C (p.Arg50Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340803"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/ee85409d-f73c-4cea-9083-d3b2f772b705","type":"EvidenceLine","dc:description":"variant absent from gnomAD, score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ee85409d-f73c-4cea-9083-d3b2f772b705_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27681997","allele":{"id":"https://genegraph.clinicalgenome.org/r/59068664-09fe-4f59-98a4-cb5cdf2e96ba","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000525.3(KCNJ11):c.601C>T (p.Arg201Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119825"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/b41ebbcb-10cb-47bf-a205-b6986935d4cd","type":"EvidenceLine","dc:description":"Variant absent from gnomAD, confirmed de novo via parental testing, score reduced due to lack of variant evidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b41ebbcb-10cb-47bf-a205-b6986935d4cd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26958039","allele":{"id":"https://genegraph.clinicalgenome.org/r/59068664-09fe-4f59-98a4-cb5cdf2e96ba"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/528b1fee-7554-4ce4-962a-5660eb8a970a","type":"EvidenceLine","dc:description":"Score altered to reflect original curation scoring - Variant absent from gnomAD, De-novo status confirmed via parental testing, scored reduced due to lack of variant evidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/528b1fee-7554-4ce4-962a-5660eb8a970a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16670688","allele":{"id":"https://genegraph.clinicalgenome.org/r/e8a327b2-6194-480f-a2e8-370a50622fd6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000525.3(KCNJ11):c.497G>T (p.Cys166Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119833"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/fbbd86f7-7c8a-499f-9dc5-ddec454478d1","type":"EvidenceLine","dc:description":"Variant reported as NM_000525.3:c.601C>G (p.Arg201Gly) in paper and Allele Registry, variant absent from gnomAD, score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fbbd86f7-7c8a-499f-9dc5-ddec454478d1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27681997","allele":{"id":"https://genegraph.clinicalgenome.org/r/9c118c4e-f963-45af-930c-09d48409ce0e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XM_017017680.1(KCNJ11):c.340C>G (p.Arg114Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA379772294"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/38852f5f-17bc-428d-bd07-f614df697091","type":"EvidenceLine","dc:description":"Score altered to reflect original curation - Variant absent from gnomAD, de novo status confirmed via parental testing, score reduced due to lack of variant evidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/38852f5f-17bc-428d-bd07-f614df697091_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16670688","allele":{"id":"https://genegraph.clinicalgenome.org/r/e622fbf5-b2e9-420b-88b9-0ae55d504534"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/6e49a957-f07e-442f-b6f6-b02441f29657","type":"EvidenceLine","dc:description":"Variant reported in paper as: NM_000525.3:c.392T>C (p.Ile131Thr), CAID pulling alternate nomenclature from ClinGen Allele registry. Variant absent from gnomAD. Score reduced due to lack of variant evidence.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6e49a957-f07e-442f-b6f6-b02441f29657_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27420379","allele":{"id":"https://genegraph.clinicalgenome.org/r/55635e71-a04c-45b6-8b96-5cc16f3c5fdd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XM_017017680.1(KCNJ11):c.131T>C (p.Ile44Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA218399931"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/e4f9aa66-bc04-4a48-ba28-97f6fca60f19","type":"EvidenceLine","dc:description":"Variant reported as NM_000525.3:c.176T>C (p.Val59Ala) in paper and Allele Registry, variant absent from gnomAD, score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e4f9aa66-bc04-4a48-ba28-97f6fca60f19_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27681997","allele":{"id":"https://genegraph.clinicalgenome.org/r/ff80498c-d879-4112-9722-759f87247519","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XM_017017680.1(KCNJ11):c.-16-70T>C (p.=)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA379775995"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/cc7ea0e5-7b47-4755-b3f4-97f3fafe1fd9","type":"EvidenceLine","dc:description":"variant absent in gnomAD, score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cc7ea0e5-7b47-4755-b3f4-97f3fafe1fd9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27681997","allele":{"id":"https://genegraph.clinicalgenome.org/r/b2699798-5cc8-49f1-b229-2a2eb972df4d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000525.3(KCNJ11):c.149G>A (p.Arg50Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA214108"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/bcb6a4d0-4a6b-45f0-8f61-826c7bc2ac52","type":"EvidenceLine","dc:description":"Variant absent from gnomAD, score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bcb6a4d0-4a6b-45f0-8f61-826c7bc2ac52_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27681997","allele":{"id":"https://genegraph.clinicalgenome.org/r/dbe043f5-0c43-48a3-bf03-3a9e0eed0a44","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000525.3(KCNJ11):c.158G>A (p.Gly53Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119837"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/b0ff494f-c39e-4d87-82ce-b8bcbe6fc6c4","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b0ff494f-c39e-4d87-82ce-b8bcbe6fc6c4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15784703","allele":{"id":"https://genegraph.clinicalgenome.org/r/e627fb9d-ba29-42e5-b67d-b2950ab74104","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000525.3(KCNJ11):c.124T>C (p.Cys42Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119829"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/b0ff494f-c39e-4d87-82ce-b8bcbe6fc6c4_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Variant absent from gnomAD. Variant Evidence: plasmids were created to express WT Kir6.2 and SUR1 or mutant Kir6.2 (isolated from proband's DNA) and WT SUR1, these were transfected into COS-1 cells which underwent patch-clamp experiments. These showed that mutant cells had reduced sensitivity to ATP in mutant channels. Mutant channels also had increased spontaneous open probability and reduced functional Katp channel expression at the cell surface. (Figs. 2-3, table 1).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/94956a48-3c8d-4fd0-9b57-f45874239567","type":"EvidenceLine","dc:description":"Variant reported as NM_000525.3:c.190G>A (p.Val64Met) in paper and Allele Registry, variant absent from gnomAD, score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/94956a48-3c8d-4fd0-9b57-f45874239567_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27681997","allele":{"id":"https://genegraph.clinicalgenome.org/r/2776a599-d4ab-4763-a322-a143644f2f29","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XM_017017680.1(KCNJ11):c.-16-56G>A (p.=)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA379775801"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/c0ffd9bd-77f0-434f-a399-5d1fb698b0a0","type":"EvidenceLine","dc:description":"Variant absent from gnomAD, score reduced due to lack of variant evidence","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c0ffd9bd-77f0-434f-a399-5d1fb698b0a0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27681997","allele":{"id":"https://genegraph.clinicalgenome.org/r/59068664-09fe-4f59-98a4-cb5cdf2e96ba"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/0296a68c-e567-4dcc-a526-b3e7802f6216","type":"EvidenceLine","dc:description":"Variant reported as NM_000525.3:c.155A>T (p.Gln52Leu) in paper and Allele Registry, variant absent from gnomAD, variant confirmed de novo via parental testing, score reduced due to lack of variant evidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0296a68c-e567-4dcc-a526-b3e7802f6216_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24150202","allele":{"id":"https://genegraph.clinicalgenome.org/r/83f06bb4-f7b9-44f7-b1c8-730ae9b91191","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XM_017017680.1(KCNJ11):c.-16-91A>T (p.=)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA379776275"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/93cd500c-c99f-4c07-9921-c24f532ea668","type":"EvidenceLine","dc:description":"Original curation scored as 2 - downgraded to 1 with SOP update","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/93cd500c-c99f-4c07-9921-c24f532ea668_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16670688","allele":{"id":"https://genegraph.clinicalgenome.org/r/b8e6d042-5c70-4859-8eea-2037faf43110"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/93cd500c-c99f-4c07-9921-c24f532ea668_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Variant absent from gnomAD, de novo status confirmed via parental testing, Variant evidence reported in PMID: 15583126 - Variant expressed in kATP channels in Xenopus oocytes and resulted in increased resting whole cell kATP currents through reduced channel inhibition by ATP","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/50ab2a3b-af42-43ee-988c-ac8052145812","type":"EvidenceLine","dc:description":"Variant reported in paper as De Novo, but this was not confirmed by parental testing. Variant absent from gnomAD, score reduced due to lack of variant evidence.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/50ab2a3b-af42-43ee-988c-ac8052145812_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16205880","allele":{"id":"https://genegraph.clinicalgenome.org/r/e622fbf5-b2e9-420b-88b9-0ae55d504534"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/43b17781-55e4-4270-ba58-831a50c8d5c0","type":"EvidenceLine","dc:description":"variant absent from gnomAD, Variant evidence reported in PMID: 15583126 - Variant expressed in kATP channels in Xenopus oocytes and resulted in increased resting whole cell kATP currents through reduced channel inhibition by ATP","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/43b17781-55e4-4270-ba58-831a50c8d5c0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27681997","allele":{"id":"https://genegraph.clinicalgenome.org/r/b8e6d042-5c70-4859-8eea-2037faf43110"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/43b17781-55e4-4270-ba58-831a50c8d5c0_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"variant absent from gnomAD, Variant evidence reported in PMID: 15583126 - Variant expressed in kATP channels in Xenopus oocytes and resulted in increased resting whole cell kATP currents through reduced channel inhibition by ATP","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9353379e-564a-43bc-a859-7d27ab640e9e_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/75948e7e-1af7-4633-8299-f48ae0a09994_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16670688","rdfs:label":"Family Angers 1","family":{"id":"https://genegraph.clinicalgenome.org/r/75948e7e-1af7-4633-8299-f48ae0a09994","type":"Family","rdfs:label":"Family Angers 1","member":{"id":"https://genegraph.clinicalgenome.org/r/73b6cf74-e8aa-4c32-8ec4-07d3ca9e2571","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16670688","rdfs:label":"ANGERS 1 II:1","ageType":"AgeAtDiagnosis","ageUnit":"Days","ageValue":17,"allele":{"id":"https://genegraph.clinicalgenome.org/r/b8e6d042-5c70-4859-8eea-2037faf43110"},"detectionMethod":"coding region and intron-exon boundaries of KCNJ11 amplified via PCR, products sequenced via capillary electrophoresis. Family relationships confirmed with panel of 10 microsattelite markers - parents tested","phenotypeFreeText":"born at term, birth weight = 2980g (11 percentile), blood glucose = 44mmol/l, ph = 6.99, treated with normal saline and insulin 0.5-0.6IU/kg/day, type 1 diabetes autoantibodies not detected, C peptide <0.2ng/ml, HbA1c = 8.2%, at 8mo showed mild axial tone, unable to sit up unaided until 10mo, walked at 18mo","phenotypes":["obo:HP_0001953","obo:HP_0002789","obo:HP_0001959","obo:HP_0001270","obo:HP_0002919","obo:HP_0002013","obo:HP_0000103"],"previousTesting":true,"previousTestingDescription":"patients with abnormalities of chromosome 6q24 and variants in GCK excluded","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/93cd500c-c99f-4c07-9921-c24f532ea668_variant_evidence_item"}}},"phenotypeFreeText":"Permanent neonatal diabetes","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/73b6cf74-e8aa-4c32-8ec4-07d3ca9e2571"}},{"id":"https://genegraph.clinicalgenome.org/r/55112f45-339c-4957-8b2f-6bb71c46b869_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22701567","rdfs:label":"Bonnefond Family F275","family":{"id":"https://genegraph.clinicalgenome.org/r/55112f45-339c-4957-8b2f-6bb71c46b869","type":"Family","rdfs:label":"Bonnefond Family F275","member":{"id":"https://genegraph.clinicalgenome.org/r/332bbd41-009d-4d6b-b5e7-4ed8236b9a62","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22701567","rdfs:label":"Bonnefond Proband IV4","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":17,"allele":{"id":"https://genegraph.clinicalgenome.org/r/d995d52b-8077-42b8-84e5-f7c82aff297c"},"detectionMethod":"WES, linkage analysis, variant confirmed with Sanger sequencing","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"BMI = 21.7 kg/m^2, treated with oral hypoglycaemic agents and sulfonylurea, FBG = 7.5 mmol/L, HbA1c = 6.8%","phenotypes":["obo:HP_0001952","obo:HP_0040217","obo:HP_0004904","obo:HP_0003074"],"secondTestingMethod":"Linkage analysis","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/8bc0b8e9-c299-444e-9d21-5a3b86ef18e0_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"impaired fasting glucose, 1 individual documented to have been diagnosed with Type 1 Diabetes","phenotypePositiveAllelePositive":9,"phenotypes":["obo:HP_0004904","obo:HP_0001952"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/332bbd41-009d-4d6b-b5e7-4ed8236b9a62"},"publishedLodScore":3.68,"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/320ea034-f336-49e1-a63d-2c186d9959b6_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16670688","rdfs:label":"Family NECKER 6","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/320ea034-f336-49e1-a63d-2c186d9959b6","type":"Family","rdfs:label":"Family NECKER 6","member":{"id":"https://genegraph.clinicalgenome.org/r/31137007-7990-4303-9324-d1af2318beaf","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16670688","rdfs:label":"NECKER 6 IV:1","allele":{"id":"https://genegraph.clinicalgenome.org/r/e622fbf5-b2e9-420b-88b9-0ae55d504534"},"detectionMethod":"coding region and intron-exon boundaries of KCNJ11 amplified via PCR, products sequenced via capillary electrophoresis. Family relationships confirmed with panel of 10 microsattelite markers - parents tested","phenotypeFreeText":"born at 38.5wks gestation after pregnancy complicated by gestational diabetes and managed by insulin pumps, birth weight = 2730g (19 percentile), blood glucose = 11.4mmol/l, insulin treatment began at 17days old at 0.5-0.6IU/kg/day, type 1 diabetes autoantibodies not detected, fasting C-peptide = 0.06mmol/l and 0.18mmol/l after IV glucagon, HbA1c = 9.5%, normal development at 16yo","phenotypes":"obo:HP_0003074","previousTesting":true,"previousTestingDescription":"patients with abnormalities of chromosome 6q24 and variants in GCK excluded","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/4255d59a-18b2-4a28-833d-550a49ebc33e_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"Permanent neonatal diabetes","phenotypeNegativeAlleleNegative":9,"phenotypePositiveAllelePositive":2,"phenotypes":"obo:HP_0009800","proband":{"id":"https://genegraph.clinicalgenome.org/r/31137007-7990-4303-9324-d1af2318beaf"}},{"id":"https://genegraph.clinicalgenome.org/r/2529bd76-4616-4f4a-a60b-ea5f911e8184_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15784703","rdfs:label":"Yorifuji Family","estimatedLodScore":0.9,"family":{"id":"https://genegraph.clinicalgenome.org/r/2529bd76-4616-4f4a-a60b-ea5f911e8184","type":"Family","rdfs:label":"Yorifuji Family","member":{"id":"https://genegraph.clinicalgenome.org/r/d903471e-2e72-4a43-87e4-5fb4d42f1f4c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15784703","rdfs:label":"IV-2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":1,"allele":{"id":"https://genegraph.clinicalgenome.org/r/e627fb9d-ba29-42e5-b67d-b2950ab74104"},"detectionMethod":"genomic DNA extracted from peripheral blood leukocytes, genome-wide linkage analysis, KCNJ11 coding region amplified via PCR then underwent direct sequencing","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"reduced insulin secretion without autoantibodies, birth weight = 2866g, HbA1c = 7.7%, C-peptide = 0.35ng/nl, negative GAD antibodies, treated with insulin until 12mo","phenotypes":["obo:HP_0030795","obo:HP_0003074","obo:HP_0000855","obo:HP_0000819"],"secondTestingMethod":"PCR","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/b0ff494f-c39e-4d87-82ce-b8bcbe6fc6c4_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"reduced insulin secretion without autoantibodies","phenotypePositiveAllelePositive":4,"phenotypes":["obo:HP_0000855","obo:HP_0000819"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/d903471e-2e72-4a43-87e4-5fb4d42f1f4c"}},{"id":"https://genegraph.clinicalgenome.org/r/d9c21a33-e704-42f7-bbb0-5be0469b35d9_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16670688","rdfs:label":"Family NECKER 29","family":{"id":"https://genegraph.clinicalgenome.org/r/d9c21a33-e704-42f7-bbb0-5be0469b35d9","type":"Family","rdfs:label":"Family NECKER 29","member":{"id":"https://genegraph.clinicalgenome.org/r/e60a4db6-1dc4-4f01-9a93-bc7171927c74","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16670688","rdfs:label":"NECKER 29 II:1","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":3,"allele":{"id":"https://genegraph.clinicalgenome.org/r/e8a327b2-6194-480f-a2e8-370a50622fd6"},"detectionMethod":"coding region and intron-exon boundaries of KCNJ11 amplified via PCR, products sequenced via capillary electrophoresis. Family relationships confirmed with panel of 10 microsattelite markers - parents tested","phenotypeFreeText":"born at 40wks gestation, birth weight = 2465g (1.6 percentile), glucose = 27mmol/l, HbA1c = 6.3%, type 1 diabetes autoantibodies not detected, diabetes controlled with insulin pump dose 0.1IU/kg/day, seizures had repeated episodes of truncal flexion associated with abnormal EEG, progressive neurological deterioration resulted in social withdrawal and poor eye contact, mild dysmorphic features, hypotonia noted as diffuse, poor trunk support, died due to aspiration pneumonia at 6mo","phenotypes":["obo:HP_0011968","obo:HP_0001250","obo:HP_0001946","obo:HP_0008846","obo:HP_0000103","obo:HP_0001508","obo:HP_0001959","obo:HP_0005487","obo:HP_0002521","obo:HP_0001488","obo:HP_0002714","obo:HP_0003074","obo:HP_0002421","obo:HP_0002353","obo:HP_0001612","obo:HP_0011951","obo:HP_0002033","obo:HP_0001290","obo:HP_0001315"],"previousTesting":true,"previousTestingDescription":"patients with abnormalities of chromosome 6q24 and variants in GCK excluded","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/528b1fee-7554-4ce4-962a-5660eb8a970a_variant_evidence_item"}}},"phenotypeFreeText":"Permanent neonatal diabetes","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/e60a4db6-1dc4-4f01-9a93-bc7171927c74"}},{"id":"https://genegraph.clinicalgenome.org/r/e5e9ca4a-1eaa-4ac9-9ffd-ffa46c6d3244_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16670688","rdfs:label":"Family NECKER 4","family":{"id":"https://genegraph.clinicalgenome.org/r/e5e9ca4a-1eaa-4ac9-9ffd-ffa46c6d3244","type":"Family","rdfs:label":"Family NECKER 4","member":{"id":"https://genegraph.clinicalgenome.org/r/d55ba017-5e07-46d7-a85b-026cb5673d9d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16670688","rdfs:label":"NECKER 4 II:1","ageType":"AgeAtDiagnosis","ageUnit":"Weeks","ageValue":4,"allele":{"id":"https://genegraph.clinicalgenome.org/r/e622fbf5-b2e9-420b-88b9-0ae55d504534"},"detectionMethod":"coding region and intron-exon boundaries of KCNJ11 amplified via PCR, products sequenced via capillary electrophoresis. Family relationships confirmed with panel of 10 microsattelite markers - parents tested","phenotypeFreeText":"Permanent neonatal diabetes, born at 38wks gestation, birth weight = 2615 (12 percentile), blood glucose = 27mmol/l, pH = 6.95, HbA1c = 7.8%, at 4wks old admitted to ICU and received IV fluid and IV insulin, cerebral oedema, did not walk until 3yo, mild dysmorphic features, clinodactyly of last 4 fingers, Median transverse palmer crease, type 1 diabetes autoantibodies not detected","phenotypes":["obo:HP_0001944","obo:HP_0001953","obo:HP_0002194","obo:HP_0003196","obo:HP_0002919","obo:HP_0002197","obo:HP_0002789","obo:HP_0004372","obo:HP_0000343","obo:HP_0008936","obo:HP_0009894","obo:HP_0040019"],"previousTesting":true,"previousTestingDescription":"patients with abnormalities of chromosome 6q24 and variants in GCK excluded, normal high-resolution karyotype","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/38852f5f-17bc-428d-bd07-f614df697091_variant_evidence_item"}}},"phenotypeFreeText":"Permanent neonatal diabetes","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/d55ba017-5e07-46d7-a85b-026cb5673d9d"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":11.9},{"id":"https://genegraph.clinicalgenome.org/r/9353379e-564a-43bc-a859-7d27ab640e9e_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9353379e-564a-43bc-a859-7d27ab640e9e_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ccab764c-2160-4722-8c63-282ce9496a19","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/95110689-adc6-4b34-954c-0a94a0e3938e","type":"Finding","dc:description":"Northern blot showed KCNJ11 expression in pancreatic islets of MIN6 and alpha-TC-6 mouse cell lines and HIT-T15 hamster cell line, expression was also shown in heart, skeletal muscle, and brain of RINm5F cell line","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7502040","rdfs:label":"Expression in Pancreatic Islets","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5e2a1b81-793a-4840-b3b4-996f86017938","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6cc86cc0-d519-4d7c-be96-b9121cb63ddf","type":"Finding","dc:description":"Expression of KCNJ11 in mouse pancreatic islet cells confirmed RT-QPCR and patch-clamp techniques. Expression at 5mM (low) glucose, mean = 30μA, at 20mM (high) glucose, mean = 34μA","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16204192","rdfs:label":"Mouse Pancreatic Islet Cell Expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/9353379e-564a-43bc-a859-7d27ab640e9e_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3f25712d-f59c-49d8-91ba-a34b1b235939","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/41bdcbb6-2b49-48a2-99f1-73285bb622ef","type":"Finding","dc:description":"Double mutant Kir6.2[ΔN2-30,K185Q] was fused at C-terminus with GFP and coexpressed with SUR1 and transfected in COSm6 cells, this showed that reconstituted Kir6.2[ΔN2-30]-GFP + SUR1 and Kir6.2[ΔN2-30,K185Q]-GFP + SUR1 channels were 7-fold and 250-fold less sensitive to inhibition by ATP than WT channels.\n\nTransgenic F1 progeny were hyperglycemic with hypoinsulinemia and had elevated blood D-3-hydroxybutyrate levels (Fig. 1, C-E), neonatal lethality was observed in all transgenic lines with most animals dying by 5 days of life (Table 1), whole body weight was reduced compared to controls and increased only through treatment with insulin (Fig. 2).\n\nTransgenic mice expressing Kir6.2[AAA] dominant-negative construct had normal blood glucose and serum insulin at day 3 (Fig. 1C,D).\n\nPancreatic isles isolated from mouse line C carrying the Kir6.2[ΔN2-30] transgene showed beta-cell specific green fluorescence, but this was absent in islets from control mice (Fig. 3), there were more fluorescent cells cells in islets from adult F1 mice, compared to C line founder mice (Fig. 3E).\n\nInside-out patch-clamp technique to measure activity of Kir6.2[ΔN2-30] mutant channels in transgenic beta cells and ATP-senstive K+ currents, this showed the Katp channels from transgenic mice have reduced sensitivity to inhibitory ATP compared to controls (Fig. 4B).\n\nImmunostaining of beta-cells from diabetic transgenic mice pancreas showed no abnormalities of islet size and distribution and no lack of insulin (Fig. 5), alpha cells showed typical peripheral distribution around core of strongly fluorescing beta-cells (Fig. 6).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10761930","rdfs:label":"Koster et al. Mouse Model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/78694c3b-714a-4e1b-9f58-62a2108ea9d0","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5904f8a7-ec8a-4c6e-a0d0-9a5eb9270092","type":"Finding","dc:description":"V59M expression confirmed in mice pancreatic islets via RT-PCR and restriction digest using cDNA from 5wk old mice, these mice were also shown to having similar KCNJ11 mRNA levels compared to WT (FIg. 2)\n\nβ-V59M mice had elevated blood glucose within 3days of life (Fig. 3C), within 5wks they had over diabetes with FBG >30mM (Fig. 3D), plasma insulin < 19pg/ml with elevated glucagon levels (Supplemental Tables 1 and 2).\n\nHypoinsulinemia of β-V59M mice determined to result from impaired glucose-dependent insulin secretion based on reduced insulin content of the islets and whole pancreas (Fig. 4 A,B), due to reduced transcription of insulin gene (Fig. 4C), and reduced basal insulin secretion evoked by glucose (Fig. 4D), it was found that Katp channel blocker tolbutamid stimulated insulin secretion in both β-V59M mice and WT mice, suggesting that reduced glucose-stimulated insulin secretion was result of Katp channel closure failure (Fig. 4D).\n\nKatp channels of β-V59M mice were shown to be less senstive to MgATP than WT beta-cells (Fig. 5 A,B, Supplemental table 3), fraction of unblocked current at 10mM ATP was increased in β-V59M beta cells (Fig. 5B), Katp currents recorded from cell-attached patches on β-V59M beta-cells were larger than WT beta-cells, and currents in excised patches were also larger (Fig. 5 C,D), whole-cell Katp currents in glucose-free solution were lager in β-V59M beta-cells than controls (Fig. 6A,B), IC50 for glucose inhibition was < 20mM, compared to 3mM for WT beta-cells (Fig. 6C).\n\nBasal calcium was similar between both β-V59M mice and controls (Fig. 7A,B, supplemental Fig. 3), glucose production in β-V59M mice had an absent initial increase and a slow secondary increase compared to WT (Fig. 7B), only 40% of cells in β-V59M islets had Ca2+ response to 20mM glucose compared to 70-90% of cell in control islets (Supplemental Table 4), and there were no Ca2+ oscillations (Fig. 7D).\n\nPercentage of insulin-containing beta-cells per islet was lower in β-V59M mice compared to WT (Fig. 8A), some islets were irregularly shaped (supplementary fig. 1A), and percentage of islet area taken up by insulin-positive beta-cells has lower in β-V59M mice compared to WT (Fig. 8B).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19065048","rdfs:label":"Girard et al. mouse model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5}],"evidenceStrength":"Definitive","sequence":5713,"specifiedBy":"GeneValidityCriteria9","strengthScore":16.9,"subject":{"id":"https://genegraph.clinicalgenome.org/r/lwTIPjK97iQ","type":"GeneValidityProposition","disease":"obo:MONDO_0015967","gene":"hgnc:6257","modeOfInheritance":"obo:HP_0000006"},"version":"2.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_9353379e-564a-43bc-a859-7d27ab640e9e-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}